Vincerx Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VINC research report →
Companyvincerx.com
Vincerx Pharma, Inc. , a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer.
- CEO
- Raquel E. Izumi
- IPO
- 2020
- Employees
- 12
- HQ
- Palo Alto, CA, US
Price Chart
Valuation
- Market Cap
- $68.05K
- P/E
- -0.01
- P/S
- 0.06
- P/B
- 0.03
- EV/EBITDA
- 0.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.00%
- Op Margin
- -1138.58%
- Net Margin
- -1216.67%
- ROE
- -542.55%
- ROIC
- -588.58%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-30,074,000 · 25.11%
- EPS
- $-5.75 · 15.94%
- Op Income
- $-31,463,000
- FCF YoY
- 35.41%
Performance & Tape
- 52W High
- $1.43
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.03
- Beta
- 1.46
- Avg Volume
- 5.08K
Get TickerSpark's AI analysis on VINC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 20, 24 | Haas Kevin | other | 0 |
| Dec 20, 24 | Haas Kevin | other | 27,875 |
| Aug 12, 24 | THOMAS TOM C | other | 175,000 |
| Aug 12, 24 | THOMAS TOM C | other | 31,250 |
| Aug 12, 24 | THOMAS TOM C | other | 93,750 |
| Aug 12, 24 | THOMAS TOM C | other | 86,000 |
| Aug 12, 24 | THOMAS TOM C | other | 58,000 |
| Aug 12, 24 | THOMAS TOM C | other | 56,000 |
| Aug 12, 24 | THOMAS TOM C | other | 55,250 |
| Aug 12, 24 | THOMAS TOM C | sell | 86,000 |
Our VINC Coverage
We haven't published any research on VINC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VINC Report →